Hochendoner v. Genzyme Corp.

E-Law Admin/ Mai 23, 2016/ Arzneimittelrecht Schweiz/ 0Kommentare

Hochendoner v. Genzyme Corp., 15-1446

In consolidated actions arising out of the shortage of a medication that treats Fabry Disease, a rare genetic disorder that leaves afflicted persons unable to synthesize a key enzyme that helps the body break down fats, the District Court’s order of dismissal is affirmed for lack of Article III standing where no specific information is provided regarding the harm, if any, that has befallen each individual plaintiff.

Appellate Information

  • Argued
  • Submitted
  • Decided
  • Published 2016/05/23

Judges

Court

  • United States First Circuit

Counsel


e-Law Trainer

Share this Post

Hinterlasse einen Kommentar